KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $12.3 million.

  • Amneal Pharmaceuticals' Capital Expenditures fell 2742.4% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.4 million, marking a year-over-year increase of 3604.88%. This contributed to the annual value of $51.9 million for FY2024, which is 2014.99% up from last year.
  • Amneal Pharmaceuticals' Capital Expenditures amounted to $12.3 million in Q3 2025, which was down 2742.4% from $22.8 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Capital Expenditures' 5-year high stood at $22.8 million during Q2 2025, with a 5-year trough of $5.0 million in Q2 2022.
  • Its 5-year average for Capital Expenditures is $12.5 million, with a median of $11.7 million in 2023.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Capital Expenditures crashed by 4075.1% in 2021, and later soared by 13773.02% in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Capital Expenditures stood at $17.5 million in 2021, then crashed by 34.47% to $11.5 million in 2022, then decreased by 13.96% to $9.9 million in 2023, then soared by 53.62% to $15.2 million in 2024, then decreased by 18.85% to $12.3 million in 2025.
  • Its Capital Expenditures was $12.3 million in Q3 2025, compared to $22.8 million in Q2 2025 and $13.2 million in Q1 2025.